Blood Test of Predicting Non-Responders of Bladder Cancer Patients to BCG Therapy

What we are studying

BCG is the most effective therapy for treating bladder cancers. However up to 40% of the treated patients failed to respond to the therapy. As a result, the non-responders’ treatment by second line therapies can be delayed for months. This research project is an effort to develop a blood test for predicting responses of bladder patients to the BCG therapy before treatment.

Who is Eligible

  • Genders:
    • Men
    • Women
  • Races:
    • White
    • African American
    • Asian
    • American Indian or Alaska Native
    • Native Hawaiian or Pacific Islander
    • Other
  • All Ethnicities
  • Ages 18+

Eligibility Criteria

  • Bladder cancer patients who will receive BCG therapy

What is involved

  • Cytoscopy
  • Biopsy
  • Blood collection


Parking will be validated for study-related visits

Contact Information

Study Coordinator
Patricia Smith
[email protected]
Principal Investigator
Ronald Davis, MD



Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.